Werewolf Therapeutics (HOWL) announced that the Company has received Fast Track Designation, FTD, for the use of WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma after standard of care immunotherapy. WTX-124 is a conditionally activated interleukin 2 INDUKINE therapy. Fast Track Designation is intended to expedite the development of drugs to address a serious unmet medical need and provide opportunities for frequent FDA interactions.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Faces Nasdaq Compliance Challenge
- Werewolf Therapeutics price target lowered to $8 from $9 at BofA
- Werewolf Therapeutics price target lowered to $3 from $4 at Citizens JMP
- Promising Advancements in Werewolf Therapeutics’ Drug Pipeline Support Buy Rating
- Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions